OmniAb (OABI) investor relations material

Platform and business model

• Transgenic mice, rats and chickens with human immune systems produce fully human antibodies for partner drug discovery.

• Biological intelligence from the animals is paired with AI-powered proprietary screening to identify antibodies against selected targets.

• Licensing generates upfront fees and may include research services, development milestones and royalties; partners develop the drugs.

• 110 partners, including 8 of the top 10 pharma companies, support 425 active programs net of attrition as of June 30.

• The 425 programs carry more than $3 billion in aggregate milestones and an average royalty rate of 3.4%.

Partner pipeline and clinical catalysts

• 34 partner drugs are in clinical development, with approximately $340 million in remaining associated milestones.

• Immunovant’s IMVT-1402 has pivotal readouts in myasthenia gravis and Graves’ disease expected next year; success could support a filing, with analyst consensus peak sales of $3 billion and launch in 2028.

• Teva’s phase II TEV-408 has reported results in celiac disease and vitiligo; further data are expected next year, with development expanding to certain dermatitis and alopecia indications.

• J&J’s ramantamig advanced from phase I directly to phase III this year; partner programs have clinical data readouts scheduled over the next 15 months.

xPloration screening platform

• xPloration screens millions of cells using imaging, AI analysis and automated laser recovery; a chip can hold about 1.5 million cells.

• Screening can deliver 100–200 antibody hits to a partner in about a day.

• The B-cell screening market was estimated at $500 million; instruments sell for $500,000 each, with recurring single-use consumables.

• Instrument sales are forecast at $2 million–$3 million this year, doubling in 2027 and doubling again in 2028.